stockrow
Friday 6 November 2026
Export IART’s income statement to Excel — free account
Integra LifeSciences Holdings Corporation
IART Healthcare Medical Devices
Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024.
- Revenue
- +2.27%
- EPS
- +371.4%
- Free cash flow
- +232.9%
- Total debt
- −0.79%
Quarter to September 2026, against a year earlier
13.41
0.71
−5.03%
Follow IART
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
95.76 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.76 | 0.84 | 0.44 | 0.58 | |
P/FCF ratio |
14.69 | 53.80 | 177.67 | 0.00 | |
P/Operating CF |
13.13 | 60.88 | 73.94 | 80.59 | |
P/B ratio |
1.18 | 1.33 | 0.70 | 0.91 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.70 | 1.84 | 1.44 | 1.53 | |
EV/EBITDA |
12.19 | 13.56 | 0.00 | 0.00 | |
EV/Operating CF |
20.04 | 35.52 | 33.23 | 49.74 | |
EV/FCF |
32.80 | 117.46 | 581.82 | (80.70) | |
Quick Ratio |
1.70 | 1.64 | 1.53 | 1.19 | |
Current Ratio |
3.62 | 3.60 | 3.38 | 2.54 | |
Net Debt/EBITDA |
24.84 | 26.60 | 30.67 | 24.86 | |
Debt/Assets |
50.69% | 51.32% | 51.06% | 50.45% | |
Debt/Equity |
1.67 | 1.75 | 1.75 | 1.74 | |
Asset Turnover |
0.46 | 0.46 | 0.43 | 0.43 | |
Operating CF/Net income |
6.46 | 5.09 | (2.12) | (6.93) | |
Capex/Depreciation |
(0.26) | (0.31) | (0.38) | (0.44) | |
Interest Coverage |
0.82 | 0.84 | 0.51 | 0.97 | |
Research and Development Expense of Revenue |
5.33% | 5.79% | 6.00% | 5.70% | |
Selling, General and Administrative Expense of Revenue |
40.20% | 41.18% | 45.48% | 38.92% | |
Intangible Assets out of Total Assets |
0.47 | 0.47 | 0.48 | 0.49 | |
Share Based Compensation of Revenue |
0.71% | 1.40% | 1.32% | 1.34% | |
Graham Net Nets |
(0.99) | (0.96) | (1.88) | (1.47) | |
Graham Number |
7.26 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
1.04% | (0.50%) | (68.58%) | (54.19%) | |
Free Cash Flow Yield |
6.81% | 1.86% | 0.56% | (3.26%) | |
Revenue per Share |
5.31 | 5.42 | 5.09 | 5.67 | |
Operating CF per Share |
1.24 | 0.30 | 0.13 | 0.15 | |
Capex per Share |
(0.13) | (0.16) | (0.19) | (0.22) | |
Free Cash Flow per Share |
1.11 | 0.14 | (0.07) | (0.07) | |
Cash per Share |
4.03 | 3.55 | 3.45 | 3.44 | |
Shareholders Equity per Share |
13.78 | 13.50 | 13.55 | 13.61 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
13.78 | 13.50 | 13.55 | 13.61 | |
Free Cash Flow |
85.73 | 10.50 | (5.04) | (5.40) | |
Working Capital |
860.94 | 860.60 | 825.17 | 703.56 | |
Capital Expenditures |
(10.25) | (12.31) | (14.85) | (17.21) | |
Net Current Asset Value |
(1,251.24) | (1,328.63) | (1,363.30) | (1,398.99) | |
EV/EBIT |
38.71 | 46.23 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.03 | 0.04 | 0.04 | |
Price to Operating Income |
17.33 | 21.18 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
255.58 | 275.85 | 258.43 | 275.61 | |
Average Payables |
79.36 | 87.74 | 89.62 | 89.11 | |
Average Inventory |
476.78 | 478.57 | 470.23 | 460.91 | |
Average Assets |
3,577.13 | 3,615.70 | 3,815.24 | 3,819.71 | |
Average Common Equity |
1,052.10 | 1,041.02 | 1,283.27 | 1,294.37 |
Columns are period end dates · fundamentals updated 2 Nov 2026